https://www.novumpr.nl/2026/06/15/new-pivotal-study-data-show-takedas-oveporexton-improved-daily-function-cognition-and-nighttime-sleep-for-people-with-narcolepsy-type-1/
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime...
newpivotalstudydatashow
https://www.pdufa.bio/drug/oveporexton
Oveporexton (TAK-861-2001): FDA Decision Dates & Catalyst History | pdufa.bio
Oct 13, 2026 - Oveporexton (TAK-861-2001): FDA approved on August 5, 2026. For Takeda Pharmaceutical Co Ltd. Catalyst history we track, every date sourced. Facts only.
oveporextontakfdadecisiondates
https://www.ajmc.com/view/oveporexton-improves-wakefulness-and-cataplexy-in-narcolepsy-type-1
Oveporexton Improves Wakefulness and Cataplexy in Narcolepsy Type 1 | AJMC
Oct 5, 2026 - Phase 3 trials found oveporexton improved wakefulness, sleepiness, and cataplexy in narcolepsy type 1, with insomnia and urinary frequency common.
oveporextonimproveswakefulnesscataplexynarcolepsy
https://www.neurologylive.com/view/fda-approves-orexin-agonist-oveporexton-narcolepsy-type-1?ref=techarcade.io
FDA Approves Orexin Agonist Oveporexton for Narcolepsy Type 1 | NeurologyLive - Clinical Neurology...
Oct 14, 2026 - The FDA has approved oveporexton, marketed as Orzeyful, as the first therapy to directly restore orexin signaling and address the full symptom range of...
orexin agonistclinical neurologyfdaapprovesoveporexton